Expression and signal transduction of T-Cell antigen receptor (TCR)/CD3 complexes on fresh or in vitro expanded t lymphocytes from patients with hodgkin's and Non-Hodgkin's lymphomas

Scandinavian Journal of Immunology

Volumn 45, Issue 6, 1997, Pages 715-725

  Rubin, B ^a,d   Martin, E P G ^a   Arnaud, J ^a   Delsol, G ^a   Plesner, T ^b   Ratsimbazafy, A ^a   Llobera, R ^a   Holm, B ^c   Mariame, B ^a  

^a CNRS   (France)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ARTICLE; B LYMPHOCYTE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0030923701     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-452.x     Document Type: Article

References (59)

1. Finkel TH, Kubo RT, Cambier JC. T-cell development and transmembrane signaling: changing biological responses through an unchanging receptor. Immunol Today 1991;12:79-85.
2. Schirrmacher V, Rubin B, Pross H, Wigzell H. Cytotoxic immune cells with specificity for defined soluble antigens. IV. Antibody as mediator of specific cytotoxicity. J Exp Med 1974;139:93-107.
3. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-74.
4. Clevers H, Alarcon B, Wileman T, Terhorst C. The T cell receptor/ CD3 complex: a dynamic protein ensemble. Ann Rev Immunol 1988;6:629-62.
5. Rubin B, Arnaud J, Caspar-Bauguil S, Conte F, Huchenq A. Biological function of the extracellular domain of the T-cell receptor constant region. Scand J Immunol 1994;39:517-25.
6. Prehn RT. Relationship of tumor immunogenecity to concentration of the oncogen. J Natl Cancer Inst 1975;55:189-90.
7. Benjamini E, Fong S, Erickson C, Leung CY, Renneick D, Scibienski RJ. Immunity to lymphoid tumors induced in syngeneic mice by immunization with mitomycin C-treated cells. J Immunol 1977; 118:685-93.
8. Hamaoka T, Fujiwara H. Phenotypically and functionally distinct T-cell subsets in anti-tumor responses. Immunol Today 1987;8:267-9.
9. Ashwell JD, Longo DL, Bridges SH. T-cell tumor elimination as a result of T-cell-mediated activation. Science 1987;237:61-6.
10. Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK. The CD28 ligand, B7 enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 1992;149:1556-61.
11. Graber M, Bockenstedt LK, Weiss A. Signaling via the inositol phospholipid pathway by T cell antigen receptor is limited by receptor number. J Immunol 1991;146:2935-43.
12. Matsuda M, Maeda Y, Shirakawa C et al. CD3 down-regulating factor in sera and culture supernatants of leukaemic cells from patients with adult T cell leukaemia. Br J Haematol 1993;83:212-17.
13. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
14. Nakagomi H, Petersson M, Magnusson I et al. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK clls of patients with colorectal carcinoma. Cancer Res 1993;53:5610-12.
15. Gunji Y, Hori T, Asano T, Ochiai T, Isono I, Saito T. High frequency of cancer patients with abnormal assembly of the T cell receptor-CD3 complex in peripheral blood T lymphocytes. Jpn J Cancer Res 1994;85:1189-92.
16. Kono K, Salazar-Onfray F, Petersson M et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996;26:1308-13.
17. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
18. Henle W, Henle G. Epstein-Barr virus and human malignancies. Adv Viral Oncol 1985;5:201-31.
19. Young L, Alfieri C, Hennessey K et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-3.
20. Sutkowski N, Palkama T, Ciurli C, Sekaly RP, Thorley-Lawson DA, Huber BT. An Epstein-Barr virus-associated superantigen. J Exp Med 1996;184:971-80.
21. Meggeto F, Al Saati T, Rubin B, Delsol G. Lack of restricted T-cell receptor β-chain variable region (V β) usage of reactive T-lymphocytes in Hodgkin's disease. Br J Haematol 1994;86:524-32.
22. Calman AF, Peterlin BM. Evidence for a trans-acting factor that regulates the transcription of class II major histocompatibility complex genes: Genetic and functional analysis. Proc Natl Acad Sci USA 1988;85:8830-4.
23. Reininger L, Fueri J, Boned A, Prat M, Landolfo S, Rubin B. On the molecular basis of T helper cell function. IV. B-lymphocyte promotor factors: On their mode of action, biochemical nature and possible relationship to molecules involved in specific T helper cell activity. Cell Immunol 1985;92:85-104.
24. Rubin B, Geisler C, Kuhlmann J, Plesner T. Fractionation of T cell subsets on Ig anti-Ig columns: Selection of CD3 negative variants of Jurkat T cells. Cell Immunol 1989;110:327-40.
25. Rubin B, Boned A. Insulin-specific T cell help to TNP-specific B cells requires activation via the T cell antigen receptor. Eur J Immunol 1986;16:1223-9.
26. Denizot F, Rubin B. Murine and human T cell factors that induce the differentiation of normal mouse lymphocytes into cytotoxic cells copurify with IL-2. Scand J Immunol 1985;22:401-13.
27. Geisler C, Kuhlmann J, Wegener AMK, Möller T, Plesner T, Rubin B. Transmembrane signalling via HLA-DR molecules on T cells from a Sezary T cell leukemia line. Scand J Immunol 1990;32:731-5.
28. Caspar-Bauguil S, Arnaud J, Gouaillard C, Hou X, Geisler C, Rubin B. Functionally important amino acids in the TCR revealed by immunoselection of membrane TCR-negative T cells. J Immunol 1994;152:5288-98.
29. Arnaud J, Chenu C, Huchenq A, Gouaillard C, Kuhlmann J, Rubin B. Defective or insufficient interactions between TCR chains and CD3 heterodimers prevent membrane expression of the TCR in human T cells. J Immunol 1996;156:2155-62.
30. Dietrich J, Neisig A, Hou X, Wegener AMK, Gajhede M, Geisler C. Role of CD3γ in T cell receptor assembly. J Cell Biol 1996;132:299-310.
31. Bismuth G, Gouy H, Mariuzza RA, Vaquero C, Theodorou I, Debre P. A human TCR-Ig chimeric protein used to generate a TCRα variable region-specific MoAb. Mol Immunol 1990;27:1127-36.
32. Wegener AMK, Holm B, Geisler C, Rubin B. Cellular and molecular characteristics of transformed T cells from an antigen-specific T-cell line. Scand J Immunol 1990;31:645-56.
33. Arnaud J, Huchenq A, Vernhes MC et al. The interchain disultide bond between αβ-T cell receptor heterodimers is not required for either TCR/CD3 membrane expression or signal transduction. Int Immunol 1997;9:615-26.
34. Rubin B, Golstein P, Nordfang O, Hertel-Wulff B. Generation of H-2 reactive T cell lines which bear the 5936 idiotype (s). J Immunol 1980;124:161-7.
35. Goldsmith MA, Weiss A. Isolation and characterization of a T-lymphocyte somatic mutant with altered signal transduction by the antigen receptor. Proc Natl Acad Sci USA 1987;84:6879-83.
36. Martin E, Huchenq A, Gas N, Arnaud J, Rubin B. Definition of a chaperon-function necessary for TCR αβ/CD3 or TCRγδ/CD3 complex interaction with ζ2 homodimers. J Biol Chem 1997 (submitted).
37. Pierres A, Lopez M, Cerdan C, Nunez J, Olive D, Mawas C. Triggering CD28 molecules synergize with CD2 (T11. 1 and T11.2)-mediated T cell activation. Eur J Immunol 1988;18:685-90.
38. Roux M, Schraven B, Roux A, Gamm H, Mertelmann R, Meuer S. Natural inhibitors of T-cell activation in Hodgkin's disease. Blood 1991;78:2365-71.
39. Ono S, Ohno H, Saito T. Rapid turnover of the CD3ζ chain independent of the TCR-CD3 complex in normal T cells. Immunity 1995;2:639-44.
40. Khattri R, Sperling AI, Qian D et al. TCR-γδ cells in CD3ζ-deficient mice contain FcεRIγ in the receptor complex but are specifically unresponsive to antigen. J Immunol 1996;157:2320-7.
41. Chien YH, Davis MM. How αβ T-cell receptors see peptide/MHC complexes. Immunol Today 1993;14:597-602.
42. Schild H, Mavaddat N, Litzenberger C et al. The nature of major histocompatibility complex recognition by γδ T cells. Cell 1994; 76:29-37.
43. Bäckström BT, Milia E, Peter A, Jaureguiberry B, Baldari CT, Palmer E. A motif within the T cell receptor α chain constant region connecting peptide domain controls antigen responsiveness. Immunity 1996;5:437-47.
44. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 1993;14:602-9.
45. Wegener AMK, Letourneur F, Hoeveler A, Brocker T, Luton F, Malissen B. The T cell receptor/CD3 complex is composed of at least two autologous transduction modules. Cell 1992;68:83-95.
46. Dietrich J, Hou X, Wegener AMK, Geisler C. CD3γ contains a phosphoserine-dependent di-leucine motif involved in down-regulation of the T cell receptor. EMBO J 1994;13:2156-66.
47. Kägi D, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. Lymphocyte-mediated cytotoxicity in vitro and in vivo: Mechanisms and significance. Immunol Rev 1995;146:95-115.
48. Rubin B, Geisler C, Caspar S, Arnaud J. The indispensable CD2-CD3 molecules. A key to T cell differentiation and functional activation. Scand J Immunol 1992;36:1-6.
49. Sakihama T, Smolyar A, Reinherz EL. Molecular recognition of antigen involves lattice formation between CD4, MHC class II and TCR molecules. Immunol Today 1995;16:581-7.
50. Valitutti S, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med 1996;183:1917-21.
51. + T-cell line. Proc Natl Acad Sci USA 1990;87:6713-17.
52. Pérez-Aciego P, Alarcon B, Arnaiz-Villena A et al. Expression and function of a variant T cell receptor complex lacking CD3γ. J Exp Med 1991;174:319-26.
53. Soudais C, de Villartay JP, le Deist F, Fischer A, Lisowska-Grospierre B. Independent mutations of the human CD3ε gene resulting in a T cell receptor/CD3 complex immunodeficiency. Nature Genetics 1993;3:77-81.
54. Mirza NM, Relias V, Yunis EJ, Pachas WN, Dasgupta JD. Defective signal transduction via T-cell receptor-CD3 structure in T cells from Rheumatoid Arthritis patients. Hum Immunol 1992;36:91-8.
55. Allen ME, Young SP, Mitchell RH, Bacon PA. Altered T lymphocyte signalling in rheumatoid arthritis. Eur J Immunol 1995;25:1547-54.
56. Renner C, Ohnesorge S, Held G et al. T cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T-cell stimulation with CD3 and CD28. Blood 1996;88:236-41.
57. Aoe T, Okamoto Y, Saito T. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 1995;181:1881-6.
58. lck and CD3 (in early thymic selection. Immunity 1995;3:215-22.
59. Baer R, Bankier AT, Biggin MD et al. DNA sequences and expression of the B95-8 Epstein-Barr genomes. Nature 1984;310:207-10.